Education
About Us
Working with TipRanks
Follow Us
CVRx (CVRX)
NASDAQ:CVRX
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.52Last Year’s EPS
-0.65Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -18.51%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted moderate revenue growth and promising clinical evidence supporting Barostim therapy. However, significant challenges included sales force realignment, seasonality impacts, and a decrease in sales territories, which hindered the company's short-term performance. Despite these challenges, the company remains optimistic about its strategic initiatives and long-term prospects.Company Guidance
During CVRx's First Quarter 2025 Earnings Conference Call, the company provided financial guidance that included expectations for full-year total revenue between $55 million and $58 million, with a gross margin between 83% and 84%. Operating expenses are projected to be between $95 million and $98 million. For the second quarter of 2025, CVRx anticipates revenue between $13 million and $14 million. The company's strategy involves enhancing their sales force, targeting high-potential centers, and addressing adoption barriers to promote their Barostim therapy. Despite a revenue performance shortfall in Q1 2025 due to sales force realignment and seasonality, CVRx remains confident in its long-term market opportunity and aims to improve sales productivity and account stabilization throughout the year. The company also highlighted ongoing efforts to improve reimbursement, expand clinical evidence, and increase awareness of their therapy.Revenue Growth
Revenue for Q1 2025 was $12.3 million, representing a 15% growth over the prior year quarter.
Expansion in Heart Failure Revenue
Heart failure revenue in the US increased to $11.1 million from $9.7 million, with a unit increase from 319 to 353.
European Market Growth
Revenue generated in Europe rose to $1.1 million, a 23% increase over the prior year.
Clinical Evidence and Adoption
Recent data demonstrated large reductions in hospital visits post-Barostim implantation: 85% in heart failure visits, 84% in cardiovascular visits, and 86% in all-cause visits.
Strategic Priorities and Sales Force Realignment
The company is focusing on building a world-class sales force, targeting high-potential centers, and addressing adoption barriers. New compensation plans have generated strong enthusiasm among the sales team.
---
CVRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CVRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $7.78 | $4.77 | -38.69% |
Feb 04, 2025 | $16.25 | $15.08 | -7.20% |
Oct 29, 2024 | $10.74 | $14.07 | +31.01% |
Jul 29, 2024 | $9.27 | $7.92 | -14.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does CVRx (CVRX) report earnings?
CVRx (CVRX) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is CVRx (CVRX) earnings time?
CVRx (CVRX) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CVRX EPS forecast?
CVRX EPS forecast for the fiscal quarter 2025 (Q2) is -0.52.
---